Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024

SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
September 05, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
August 28, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
August 12, 2024 16:05 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trialsOn track to advance multiple pre-IND assets into the clinic in the next 12-18 monthsMaking continued...
July 30, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
July 22, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
June 12, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
June 11, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
June 10, 2024 16:10 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
May 24, 2024 08:01 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...